Silexion Therapeutics Ltd.
SLXNW · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $6 | $4 | $0 | $0 |
| G&A Expenses | $0 | $1 | $0 | $0 |
| SG&A Expenses | $7 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $13 | $5 | $1 | $1 |
| Operating Income | -$13 | -$5 | -$1 | -$1 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$4 | -$0 | $2 | $0 |
| Pre-Tax Income | -$17 | -$5 | $1 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$16 | -$5 | $1 | -$1 |
| % Margin | – | – | – | – |
| EPS | 25.49 | 0.39 | 0.35 | -0.46 |
| % Growth | 6,435.9% | 11.4% | 176.1% | – |
| EPS Diluted | 25.49 | 0.39 | 0.35 | -0.46 |
| Weighted Avg Shares Out | 1 | 1 | 2 | 2 |
| Weighted Avg Shares Out Dil | 1 | 1 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $2 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$16 | -$5 | $1 | -$1 |
| % Margin | – | – | – | – |